phase 2_initiation
saveNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 0 trial initiationWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)Apr 30, 2026 · 160d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalNov 25, 2025 · 316d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 2, 2025 · 370d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 29, 2024 · 708d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalOct 29, 2024 · 708d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalAug 7, 2024 · 791d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalJun 18, 2024 · 841d ago
- approvalSCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalNov 8, 2023 · 1064d ago
same company · ±60 days · 6
- earningsNOVARTIS AG earningsApr 28, 2026
- phase 1 2 completionzigakibart: Novartis AG — zigakibart (Phase I/II Trial Completion)Apr 30, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalApr 17, 2026
related news · 1
🐶 often sniffed alongside
top 7- drugSCEMBLIX46 co-mentions · 13 sources
- tagApproval44 co-mentions · 11 sources
- tagSmall Molecule22 co-mentions · 11 sources
- tagOncology3 co-mentions · 2 sources
- company$NVSNOVARTIS AG1 co-mentions · 1 sources
- company$NVSEFNOVARTIS AG1 co-mentions · 1 sources
- companyWashington University School of Medicine1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that